IN CASE YOU MISSED IT: This week, Morning Consult published an op-ed by Matthew Lane, executive director of the Coalition Against Patent Abuse, around rising prescription drug prices and the need for reforms that can encourage competition and innovation to drive access and affordability.  In his op-ed, Lane highlights a recent national survey by the Campaign for Sustainable Rx Pricing, […]

Continue Reading

IN CASE YOU MISSED IT: This week, Axios reported that Humira, a medicine that treats a number of chronic conditions and is widely prescribed and used by millions of people around the world, reached $19.9 billion in global sales in 2018, marking an 8.2 percent increase from 2017.  While Humira is notably one of the most profitable […]

Continue Reading

WASHINGTON, DC: In case you missed it, STAT today highlighted a new analysis that shows AbbVie could have its patents on cancer drug Imbruvica extended through 2036, forcing consumers to spend an additional $41 billion for the cancer treatment drug.  As I-MAK details in a new report, this move would prevent cheaper generic alternatives from entering the market […]

Continue Reading

WASHINGTON, DC: In case you missed it, Politico today highlighted the significant drug pricing hikes made by big pharmaceutical companies as millions of patients struggle to access affordable drugs amidst the coronavirus pandemic.  This year alone, big Pharma companies conducted hundreds of new price increases on patients which would appear to confirm the fears of many Americans.  […]

Continue Reading

IN CASE YOU MISSED IT: This week, Morning Consult published an op-ed by Matthew Lane, executive director of the Coalition Against Patent Abuse, around reforming the patent system to balance competition and innovation so that American patients have access to affordable drugs, especially as both the private and public sectors work to quickly discover a treatment for COVID-19.  […]

Continue Reading

IN CASE YOU MISSED IT: Recently, HealthAffairs highlighted a study by researchers at Brigham and Women’s Hospital and Harvard Medical School that showed the real effects of name-brand drug manufacturers maintaining their market exclusivity by preventing of generic competition from entering the marketplace.  Among 61 name-brand drugs at risk of losing their market exclusivity from 2010-2016, 45 […]

Continue Reading

IN CASE YOU MISSED IT: This week, Townhall published an op-ed by Wayne Brough, President of the Innovation Defense Foundation, on the challenging task policymakers have in thwarting threats that could hinder the nation’s economic recovery from COVID-19.  As we work as a nation to financially rebuild, lawmakers must also consider the constrains that bad patent laws can have […]

Continue Reading

IN CASE YOU MISSED IT: Recently, The Hill published a timely op-ed by Matthew Lane, executive director of the Coalition Against Patent Abuse.  Lane penned this piece amidst the COVID-19 pandemic to highlight the need to make sure our drug laws are working to encourage innovation and public-private partnerships for the development of needed drugs while preventing […]

Continue Reading

By Matthew Lane, Executive Director of the Coalition Against Patent Abuse (CAPA) On March 9, 2020, the Food and Drug Administration (FDA) and Federal Trade Commission (FTC) held a public workshop to discuss their collaborative efforts to support appropriate adoption of biosimilars, discourage false or misleading statements about biosimilars, and deter anticompetitive behaviors in the […]

Continue Reading

WASHINGTON, DC: On the 10th anniversary of the Biologics Price Competition and Innovation Act (BPCIA) that created biosimilars, The ERISA Industry Committee (ERIC) released a study on the potential savings employers and employees could have with increased biosimilars in the marketplace.  Inside Health Politicscovered the study which found that biologics – the most expensive class of […]

Continue Reading